Shock Clinical Trial
Official title:
Hydrogen Sulfide as Prognostic Factor
Hydrogen sulfide (H2S), better known as a poisonous gas, has emerged as the third gaseous transmitter in mammals, next to nitric oxide (NO) and carbon monoxide (CO). Increased production and higher serum concentrations were shown in inflammatory diseases, septic shock and stroke. The investigators will test the hypothesis that higher serum H2S concentrations on admission to intensive care unit (ICU) are linked with higher mortality in patients with shock of any reason.
Hydrogen sulfide (H2S), better known as a poisonous gas, has lately emerging as a third
gaseous transmitter in mammals, next to nitric oxide (NO) and carbon monoxide (CO). H2S is
present in most human tissues in concentrations up to 50 μM. Most of it is synthesized in
brain, cardiovascular system, kidneys and liver. In human tissues H2S is synthesized from
L-cysteine by two enzymes cystathionine-γ-lyase and cystathionine-β-synthase. H2S works by
stimulating ATP sensitive potassium channels and is involved in regulation of vascular tone,
myocardial contractility, insulin secretion and neurotransmission. In numerous animal
models, H2S deficiency was shown in arterial and pulmonary arterial hypertension,
Alzheimer's disease and liver cirrhosis. Increased production and higher serum
concentrations were shown in inflammatory diseases, septic shock and stroke.
Most of studies so far were conducted on animals and already show some therapeutic
potentials. In available literature there have been no studies in humans focused on H2S
concentrations in critically ill and its prognostic value.
Hypothesis We will test the hypothesis that higher serum H2S concentrations on admission to
ICU are linked with higher mortality in patients with shock of any reason.
Serum H2S concentrations are related to treatment support with vaso-active drugs
(noradrenalin, epinephrine).
Material and methods In the study we will include adult patients admitted to medical ICU due
to shock of any reason. Shock is defined as systemic arterial pressure lower than 90mmHg or
drop for systemic arterial pressure at least 40mmHg for 15minutes or more with elevation of
serum lactate value.
Patients will be included on basis of clinical appearance of shock - hypotension or need for
vasopressors, brady- or tachycardia, signs of peripheral hypo perfusion, oliguria and
changes in mental status.
Exclusion criteria: patient younger then 18years and patients not in shock
From blood samples drawn on admission to ICU we will measure H2S concentration. H2S
concentration will be measured spectrophotometrically5 as first described in 19496 and
further refined in 19657. Spectrophotometrical determination of H2S concentration in tissue
and plasma was previously used by many researchers.3,8-11 Blood samples will be centrifuged
as quickly after collection to obtain plasma. 200 μL of plasma will be mixed with
pre-prepared solution of 100 μL 10% (wt/vol) trichloroacetic acid and 60 μL 1% (wt/vol) zinc
acetate, to trap dissolved H2S. The mixture will be frozen at 20 C until further analysis.
After sufficient number of samples will be obtained, we will measure H2S concentration in
series. 40µL 20 µM N,N-dimethyl-p-phenylenediamine sulfate in 7,2 M HCl and 40µL 30 µM FeCl3
v 1,2 M HCl will be added to unfrozen samples. After 10-20 min incubation at room
temperature final mixtures will be centrifuged at 9000 rpm for 5 minutes to remove
precipitate. After centrifugation absorption at 670 nm will be measured with
spectrophotometer. All analysis will be done in duplicates.
Calibration curve of absorbance versus sulfide concentration will be obtained from known
concentration of Na2S (0,699 µM - 69,93 µM) and concentrations of H2S in plasma calculated.
Impact of plasma H2S concentration on admission to ICU on ICU mortality will be observed
trough nonparametric statistical analysis.
Expectations We hypothesize that higher serum H2S concentrations on admission to ICU in
patients with shock of any cause are indicators of severity of shock and cardiovascular
deterioration, related to treatment support with vaso-active drugs (noradrenalin,
epinephrine). Thus higher serum H2S concentrations are expected to be better prognostic
factor of ICU mortality in patients with shock than currently established lactic acid.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05898126 -
Renin-guided Hemodynamic Management in Patients With Shock
|
N/A | |
Completed |
NCT05563701 -
Evaluation of the LVivo Image Quality Scoring (IQS)
|
||
Recruiting |
NCT05066256 -
LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock
|
N/A | |
Not yet recruiting |
NCT06285513 -
Cardiovascular Metabolic Remodeling in Shock
|
||
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Terminated |
NCT02755155 -
Optimization of Therapeutic Human Serum Albumin Infusion in Selected Critically Ill Patients
|
Phase 4 | |
Not yet recruiting |
NCT01941472 -
Transcutaneous pO2, Transcutaneous pCO2 and Central Venous pO2 Variations to Predict Fluid Responsiveness
|
N/A | |
Completed |
NCT01680783 -
Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure
|
N/A | |
Terminated |
NCT01696175 -
PICU Admission Lactate and Central Venous Oxymetry Study
|
N/A | |
Recruiting |
NCT01157299 -
Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO
|
N/A | |
Recruiting |
NCT01174966 -
Assessment of Transcutaneous Oxygen Tension/Oxygen Challenge Test in Intensive Care Unit (ICU) Patients
|
N/A | |
Completed |
NCT00743522 -
Programming Implantable Cardioverter Defibrillators in Patients With Primary Prevention Indication
|
||
Completed |
NCT03296891 -
Point of Care Ultrasonography In The Management of Shock: A Pilot Study
|
N/A | |
Recruiting |
NCT05922982 -
Norepinephrine Weaning Guided by the Hypotension Prediction Index in Vasoplegic Shock After Cardiac Surgery
|
N/A | |
Withdrawn |
NCT04705701 -
Comparing Post Cardiac Surgery Outcomes in ESRD Patient's With Early Dialysis Versus Standard Care
|
N/A | |
Recruiting |
NCT04615065 -
Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
|
||
Completed |
NCT05330676 -
Evaluation of Microcirculatory Function and Mitochondrial Respiration After Cardiovascular Surgery
|
||
Active, not recruiting |
NCT04079829 -
Postoperative Respiratory Abnormalities
|
||
Completed |
NCT04089098 -
VOLume and Vasopressor Therapy in Patients With Hemodynamic instAbility
|
||
Completed |
NCT03190408 -
Variation in Fluids Administered in Shock
|